Pharmabiz56m
Only 4 out of 46 companies inspected showed 100% compliance with Revised Schedule M in Tamil Nadu
Only 4 out of 46 companies inspected showed 100% compliance with Revised Schedule M in Tamil Nadu: Peethaambaran Kunnathoor, Chennai Tuesday, November 19, 2024, 08:00 Hrs [IST] In ...
Pharmabiz56m
DGFT overhauls export policy through harmonisation with ITC (HS) 2022 to streamline pharma export process
DGFT overhauls export policy through harmonisation with ITC (HS) 2022 to streamline pharma export process: Shardul Nautiyal, Mumbai Tuesday, November 19, 2024, 08:00 Hrs [IST] Wit ...
Pharmabiz54m
Independent labs play crucial role in various stages of drug development: Dr. Saurabh Arora
In the pharmaceutical industry, ensuring the safety, efficacy, and quality of drugs is an ongoing and intricate process. Independent testing laboratories, like Auriga Research, play a critical role ...
Pharmabiz56m
Unified mechanism under FSSAI for nutraceuticals would help rather than having two authorities: Expert
Unified mechanism under FSSAI for nutraceuticals would help rather than having two authorities: Expert: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] A unifi ...
Pharmabiz56m
SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab
SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...
Pharmabiz18h
EMA encourages companies to submit type I variations for 2024 by end November 2024
EMA encourages companies to submit type I variations for 2024 by end November 2024: Amsterdam, The Netherlands Monday, November 18, 2024, 14:00 Hrs [IST] European Medicines Agency ...
Pharmabiz17h
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
Pharmabiz9h
Molbio supports Azerbaijan's 'TB go green' initiative at COP29 with pioneering TB diagnostic solutions
As part of a concerted effort to combat tuberculosis (TB) with a focus on climate change, Molbio Diagnostics, an innovator in global healthcare has contributed a donation of their state-of-the-art TB ...
Pharmabiz16h
Augurex Life Sciences, Quest Diagnostics collaborate to improve rheumatoid arthritis diagnosis and management
Augurex Life Sciences, Quest Diagnostics collaborate to improve rheumatoid arthritis diagnosis and management: Vancouver, Canada Monday, November 18, 2024, 16:00 Hrs [IST] Augurex ...
Pharmabiz21h
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
Pharmabiz22h
iiCON funds 11 new innovative projects focused on tackling infectious diseases
After successful sandpit events in Liverpool and London earlier this year, iiCON (Infection Innovation Consortium) is excited to announce 11 new projects during World AMR Awareness Week. These ...
Pharmabiz15h
Boston Pharma announces positive phase 2 data on efimosfermin alfa, a long-acting FGF21 analogue in patients with stage F2/F3 fibrosis due to MASH
Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, announced positive results from a phase 2 study evaluating the ...